methylbis(propan-2-yl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide

• ChemBase编号: 662
• 分子式: C23H30BrNO3
• 平均质量: 448.3932
• 单一同位素质量: 447.14090583
• SMILES: O(CC[N+](C(C)C)(C(C)C)C)C(=O)C1c2c(Oc3c1cccc3)cccc2.[Br-]
• Canonical SMILES: O=C(C1c2ccccc2Oc2c1cccc2)OCC[N+](C(C)C)(C(C)C)C.[Br-]
• InChI: InChI=1S/C23H30NO3.BrH/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22;/h6-13,16-17,22H,14-15H2,1-5H3;1H/q+1;/p-1
• InChIKey: XLBIBBZXLMYSFF-UHFFFAOYSA-M

名称和登记号

名称

• IUPAC标准名: methylbis(propan-2-yl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide
• IUPAC传统名: propantheline bromide; diisopropyl(methyl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide
• 商标名: Pro-Banthine; Propanthel
• 别名: Propantheline Bromide; Propanthelinium; Propanthelinum; Propantheline; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; PROPANTHELINE BROMIDE; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; Propantheline bromide; N-Methyl-N-(1-methylethyl)-N-[2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl]-2-propanaminium Bromide; Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neo-Metantyl; Neopepulsan; Pantas; Pervagal; Pro-Banthine; Pro-Gastron; Prodixamon; Propantel; SC 3171; β-Diisopropylaminoethyl Xanthene-9-carboxylate Methobromide

登记号

• CAS号: 50-34-0; 298-50-0
• EC号: 200-030-6
• MDL号: MFCD00050291
• PubChem SID: 46507187; 24278660; 160964125
• PubChem CID: 9279; 4934

理论计算性质

JChem

• Acid pKa: 18.098024
• 质子受体: 1
• 质子供体: 0
• LogD (pH = 5.5): 0.36379364
• LogD (pH = 7.4): 0.36379364
• Log P: 0.36379364
• 摩尔折射率: 119.2545 cm^3
• 极化性: 42.411964 Å^3
• 极化表面积: 35.53 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.66
• LOG S: -6.75
• 溶解度: 7.22e-05 g/l

分子性质

理化性质

• 溶解度: Chloroform; H2O: soluble50 mg/mL; Methanol
• 外观: White Solid; white to off-white powder
• 熔点: 159-161 °C; 165-167°C

安全信息

• 保存条件: Refrigerator; Room Temperature (15-30°C)
• RTECS编号: BP8249200
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22; R:22
• 安全公开号: 36; S:36/37/39
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 个人保护装置: dust mask type N95 (US), Eyeshields, Faceshields, Gloves

药理学性质

• 相关基因信息: human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)

产品相关信息

• 纯度: ≥97% (TLC)
• 线性分子式: C23H30NO3Br

详细说明

MP Biomedicals - 02156392

Crystalline

DrugBank - DB00782

• Drug Groups: approved
• Description: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. [PubChem]
• Indication: For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.
• Pharmacology: Propantheline is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Propantheline is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Propantheline inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.
• Affected Organisms: Humans and other mammals
• Elimination: Approximately 70% of the dose is excreted in the urine, mostly as metabolites.
• External Links: Wikipedia; Drugs.com

Sigma Aldrich - P8891

Biochem/physiol Actions
Inhibits action of acetylcholine at post-ganglionic synapses; muscarinic acetylcholine receptor antagonist; antispasmodic; reduces gastric acid secretion.

Toronto Research Chemicals - P760900

Propantheline is an antimuscarinic agent used in the treatment of hyperhidrosis (excessive sweating), enuresis (involuntary urination) as well as cramps or spasms of the stomach, intestine and bladder.

参考文献

• Levin, R. et al.: Neurol. Urodyn., 1, 221 (1982)
• Daniotti, S. et al.: Br. J. Pharmacol., 82, 305 (1982)
• Moller, J. et al .: Acta Med. Scand., 184, 201 (1982)